NCT06208735View on ClinicalTrials.gov

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 2, 2025

Primary Completion Date

August 1, 2026

Study Completion Date

August 1, 2027

Conditions
B-Cell LeukemiaNon-Hodgkin's LymphomaB-cell Acute Lymphoblastic LeukemiaDiffuse Large B Cell LymphomaHigh-grade B-cell LymphomaPrimary Mediastinal Large B-cell Lymphoma (PMBCL)Mantle Cell LymphomaB-cell Lymphoma
Interventions
BIOLOGICAL

CLIC-2201

Participants will undergo (a) lymphodepletion with cyclophosphamide and fludarabine, followed by (b) infusion of autologous CLIC-2201 CAR-T cells. All treatments will be delivered intravenously.

Trial Locations (7)

T2N 5G2

RECRUITING

Arthur J.E. Child Comprehensive Cancer Centre, Calgary

T3B 6A8

RECRUITING

Alberta Children's Hospital, Calgary

V5Z 1M9

RECRUITING

Vancouver General Hospital, Vancouver

Unknown

RECRUITING

BC Children's Hospital, Vancouver

NOT_YET_RECRUITING

Princess Margaret Cancer Centre, Toronto

RECRUITING

The Hospital for Sick Children, Toronto

K1H 8L6

RECRUITING

The Ottawa Hospital - General Campus, Ottawa

All Listed Sponsors
lead

British Columbia Cancer Agency

OTHER